ES2013324A6 - Un metodo mejorado para producir una proteina heterologa. - Google Patents

Un metodo mejorado para producir una proteina heterologa.

Info

Publication number
ES2013324A6
ES2013324A6 ES8703256A ES8703256A ES2013324A6 ES 2013324 A6 ES2013324 A6 ES 2013324A6 ES 8703256 A ES8703256 A ES 8703256A ES 8703256 A ES8703256 A ES 8703256A ES 2013324 A6 ES2013324 A6 ES 2013324A6
Authority
ES
Spain
Prior art keywords
improved
expression system
protein
heterologous
eucaryotic expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES8703256A
Other languages
English (en)
Inventor
Randal J Kaufman
Andrew Dorner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute LLC filed Critical Genetics Institute LLC
Publication of ES2013324A6 publication Critical patent/ES2013324A6/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

UN METODO MEJORADO PARA PRODUCIR UNA PROTEINA HETEROLOGA. COMPRENDE CULTIVAR UNA CELULA HUESPED, O SU PROGENIE, TRANSFORMADA CON UN VECTOR CAPAZ DE DIRIGIR LA EXPRESION DE LA PROTEINA HETEROLOGA, CUYA CELULA HUESPED ESTA ADICIONALMENTE TRANSFORMADA CON UN VECTOR SELECCIONADO DEL GRUPO FORMADO POR: A) UN VECTOR DE EXPRESION ANTISENTIDO GRP78/BIP, B) UN VECTOR QUE CONTIENE UNA SECUENCIA DE DNA DETERMINADA, O C) COMBINACION DE LOS VECTORES (A) Y (B), EFECTUANDOSE DICHO CULTIVO DURANTE POR LO MENOS 4 HORAS BAJO CONDICIONES AEROBICAS EN UN MEDIO DE CULTIVO DE CELULAS MANTENIDO A 37GC APROXIMADAMENTE. APLICACION PARA LA SINTESIS DE PROTEINAS POR INGENIERIA GENETICA.
ES8703256A 1986-11-14 1987-11-13 Un metodo mejorado para producir una proteina heterologa. Expired - Fee Related ES2013324A6 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93138186A 1986-11-14 1986-11-14
US07/010,351 US4912040A (en) 1986-11-14 1987-02-03 Eucaryotic expression system

Publications (1)

Publication Number Publication Date
ES2013324A6 true ES2013324A6 (es) 1990-05-01

Family

ID=26681064

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8703256A Expired - Fee Related ES2013324A6 (es) 1986-11-14 1987-11-13 Un metodo mejorado para producir una proteina heterologa.

Country Status (9)

Country Link
US (1) US4912040A (es)
EP (1) EP0289597B1 (es)
JP (1) JPH01501363A (es)
KR (1) KR890700164A (es)
AU (1) AU1100288A (es)
CA (1) CA1297436C (es)
DE (1) DE3789017D1 (es)
ES (1) ES2013324A6 (es)
WO (1) WO1988003558A1 (es)

Families Citing this family (273)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272065A (en) * 1983-10-20 1993-12-21 Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5208149A (en) * 1983-10-20 1993-05-04 The Research Foundation Of State University Of New York Nucleic acid constructs containing stable stem and loop structures
US5190931A (en) * 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6060447A (en) * 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5965405A (en) * 1988-04-16 1999-10-12 Celltech Limited Method for producing Fv fragments in eukaryotic cells
US5340739A (en) * 1988-07-13 1994-08-23 Brigham & Women's Hospital Hematopoietic cell specific transcriptional regulatory elements of serglycin and uses thereof
US5942389A (en) * 1990-10-19 1999-08-24 Board Of Trustees Of The University Of Illinois Genes and genetic elements associated with sensitivity to cisplatin
US5866327A (en) * 1990-10-19 1999-02-02 Board Of Trustees Of The University Of Illinois Association of kinensin with sensitivity to chemotherapeutic drugs
US5665550A (en) * 1990-10-19 1997-09-09 Board Of Trustees Of The University Of Illinois-Urbana Genes and genetic elements associated with sensitivity to chemotherapeutic drugs
US5217889A (en) * 1990-10-19 1993-06-08 Roninson Igor B Methods and applications for efficient genetic suppressor elements
EP0785273A1 (en) 1990-11-26 1997-07-23 Genetics Institute, Inc. Paired basic amino acid converting enzyme and DNA sequence encoding it
US6268134B1 (en) 1993-09-07 2001-07-31 Board Of Trustees Of University Of Il Method and applications for efficient genetic suppressor elements
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
WO1994026908A1 (en) * 1993-05-17 1994-11-24 Genentech, Inc. Cho cell sialidase by recombinant dna technology
US6562588B2 (en) * 1993-05-17 2003-05-13 Genentech, Inc. Sialidase and recombinant cell lines
AU1960495A (en) * 1995-03-17 1996-10-08 Chihiro Koike Transformant of nonprimatial mammal having serotype of advanced primate expressed by foreign gene transduction and process for producing the same
ZA959429B (en) * 1995-11-07 1996-07-11 Interpharm Lab Ltd Use of anti-sense sequences to increase responsiveness to gene amplification
US6399377B1 (en) 1995-11-27 2002-06-04 Yves Mory Use of anti-sense sequences to increase responsiveness to gene amplification
US8183344B2 (en) 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
PT1754718E (pt) 1996-04-24 2011-07-13 Univ Michigan Factor viii resistente à inactivação
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP0927757A1 (en) * 1997-12-03 1999-07-07 Leadd B.V. Methods and means for inducing apoptosis by interfering with Bip-like proteins
ATE222925T1 (de) 1998-03-12 2002-09-15 Inst Genetics Llc Verbessertes verfahren zur herstellung von faktor viii
US7820796B2 (en) 1998-03-12 2010-10-26 Genetics Institute, Llc. Methods for producing Factor VIII proteins
US6803448B1 (en) * 1998-07-22 2004-10-12 Vanderbilt University GBS toxin receptor
US8609614B2 (en) * 1998-07-22 2013-12-17 Vanderbilt University GBS toxin receptor compositions and methods of use
US6682736B1 (en) * 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US20050074747A1 (en) * 2000-09-08 2005-04-07 Wadih Arap Biopanning and rapid analysis of selective interactive ligands (brasil)
US20040170955A1 (en) 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US7420030B2 (en) 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
NZ527302A (en) 2001-01-05 2006-10-27 Abgenix Inc Antibodies to insulin-like growth factor I receptor
US7615622B2 (en) 2001-01-12 2009-11-10 University Of Maryland, Baltimore Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
JP2005519580A (ja) * 2001-05-16 2005-07-07 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ 非ヒト動物由来のヒト抗肺炎球菌抗体
AU2002316384A1 (en) * 2001-06-26 2003-03-03 Photomed Technologies, Inc. Multiple wavelength illuminator
TR201809678T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
US20040176290A1 (en) * 2001-07-18 2004-09-09 Renata Pasqualini Anti-angiogenic state in mice and humans with retinal photorecptor cell degeneration
US7671010B2 (en) * 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US8507445B2 (en) * 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US20040048243A1 (en) * 2001-09-07 2004-03-11 Wadih Arap Methods and compositions for in vitro targeting
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
AU2003243139B2 (en) * 2002-04-05 2007-06-21 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
MXPA04011624A (es) 2002-05-24 2005-03-07 Schering Corp Anticuerpo neutralizante humano anti-igfr.
MXPA05002514A (es) 2002-09-06 2005-05-27 Amgen Inc Anticuerpo monoclonal anti-il-1r1 humano terapeutico.
US7396913B2 (en) * 2002-10-14 2008-07-08 Abbott Laboratories Erythropoietin receptor binding antibodies
WO2004034988A2 (en) 2002-10-16 2004-04-29 Amgen Inc. Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
JP4754219B2 (ja) 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用
CA2519528C (en) 2003-03-19 2016-01-26 Abgenix, Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
MXPA05014155A (es) 2003-06-27 2006-05-25 Abgenix Inc Anticuerpos dirigidos a los mutantes de delecion de receptor de factor de crecimiento epidermico y sus usos.
US7244616B2 (en) 2003-06-27 2007-07-17 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
EA015363B1 (ru) 2003-07-18 2011-06-30 Эмджен Инк. Агенты, специфически связывающие фактор роста гепатоцитов, и их применение
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
CN1838968A (zh) 2003-08-08 2006-09-27 艾伯吉尼斯公司 针对甲状旁腺激素(pth)之抗体和其用途
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
US8541002B2 (en) * 2003-09-12 2013-09-24 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection
ATE509269T1 (de) * 2003-10-27 2011-05-15 Univ Southern California Verfahren und verbindungen zur modulierung von apoptosis
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
DOP2005000002A (es) 2004-01-09 2005-08-15 Pfizer "anticuerpos contra madcam"
WO2005092926A2 (en) 2004-03-19 2005-10-06 Amgen Inc. Reducing the risk of human and anti-human antibodies through v gene manipulation
CA2560889A1 (en) * 2004-03-23 2005-10-13 Sanjay D. Khare Monoclonal antibodies specific for human ox40l (cd 134l)
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
CN101014365B (zh) * 2004-07-16 2011-04-13 辉瑞产品公司 使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤
JP5014130B2 (ja) 2004-08-02 2012-08-29 ズィナイス オペレーションズ ピーティーワイ．エルティーディー． Ｖｅｇｆ−ｂアンタゴニストを含む癌治療方法
ES2414460T3 (es) 2004-08-04 2013-07-19 Amgen Inc. Anticuerpos para Dkk-1
CA2585719A1 (en) 2004-11-08 2006-05-18 Schering Corporation Tumor association of mdl-1 and methods
WO2006055638A2 (en) 2004-11-17 2006-05-26 Abgenix, Inc. Fully human monoclonal antibodies to il-13
US7572444B2 (en) 2004-12-20 2009-08-11 Amgen Fremont Inc. Binding proteins specific for human matriptase
ZA200705695B (en) 2004-12-21 2009-02-25 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
EP2361933A3 (en) 2005-01-26 2012-05-02 Amgen Fremont Inc. Antibodies against interleukin-1 beta
EP1865986B1 (en) 2005-03-08 2016-02-17 Pfizer Products Inc. Anti-ctla-4 antibody compositions
TW200724548A (en) * 2005-04-25 2007-07-01 Pfizer Antibodies to myostatin
EP1877444A2 (en) 2005-04-26 2008-01-16 Pfizer, Inc. P-cadherin antibodies
DK1915398T3 (en) 2005-07-18 2016-07-04 Amgen Inc Humane anti-B7RP1 neutraliserende antistoffer
CA2615460A1 (en) * 2005-08-08 2007-02-15 Onconon, Llc Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
SI2447283T1 (sl) 2005-09-07 2015-12-31 Amgen Fremont Inc. Človeška monoklonska protitelesa proti aktivin receptorski kinazi-1 (ALK-1)
EP1957115B8 (en) 2005-11-10 2014-03-05 Celldex Therapeutics, Inc. Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
AR056806A1 (es) 2005-11-14 2007-10-24 Amgen Inc Moleculas quimericas de anticuerpo rankl- pth/ pthrp
PL1979001T3 (pl) 2005-12-13 2012-09-28 Medimmune Ltd Białka wiążące specyficzne dla insulinopodobnych czynników wzrostu i ich zastosowania
EP1962903B1 (en) 2005-12-15 2013-03-13 MedImmune Limited Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
AU2007234733A1 (en) * 2006-04-07 2007-10-18 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Antibody compositions and methods for treatment of neoplastic disease
ES2828739T3 (es) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
EP2007804B1 (en) 2006-04-20 2014-06-18 Amgen, Inc Glp-1 compounds
US7745584B2 (en) * 2006-05-22 2010-06-29 California Institute Of Technology Antibodies to sulfated carbohydrates
US20080070251A1 (en) 2006-06-30 2008-03-20 Kaufman Randal J Method of Producing Factor VIII Proteins by Recombinant Methods
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
KR20090058512A (ko) 2006-08-04 2009-06-09 아스트라제네카 아베 Ｅｒｂｂ2에 대한 인간 항체
AU2007283463B2 (en) 2006-08-11 2012-04-26 Csl Limited Treatment of pulmonary disease conditions
ZA200904022B (en) 2006-12-08 2010-08-25 Lexicon Pharmaceuticals Inc Monoclonal antibodies against ANGPTL3
JP5718640B2 (ja) 2007-08-21 2015-05-13 アムジエン・インコーポレーテツド ヒトｃ−ｆｍｓ抗原結合性タンパク質
EP4248976B1 (en) 2007-08-23 2026-04-22 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
KR101652125B1 (ko) 2007-09-26 2016-08-29 우드라이 파마 게엠베하 헤파린-결합 표피 성장 인자-유사 성장 인자 항원 결합 단백질
CA2703544C (en) 2007-10-26 2016-01-05 Manuel Baca Cytokine muteins
EP3211011A1 (en) 2007-11-16 2017-08-30 Nuvelo, Inc. Antibodies to lrp6
US8912149B1 (en) 2007-11-28 2014-12-16 California Institute Of Technology Glycosaminoglycan mimetics
SI2242771T1 (sl) 2007-12-14 2013-09-30 Bristol-Myers Squibb Company Vezane molekule k humanemu ox40 receptorju
CN102264763B (zh) 2008-09-19 2016-04-27 米迪缪尼有限公司 定向于dll4的抗体及其用途
WO2010067308A2 (en) 2008-12-08 2010-06-17 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
EP2379595A2 (en) 2008-12-23 2011-10-26 AstraZeneca AB Targeted binding agents directed to 5 1 and uses thereof
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
CA2769473A1 (en) 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
WO2011017294A1 (en) 2009-08-07 2011-02-10 Schering Corporation Human anti-rankl antibodies
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
EP2477656B1 (en) 2009-09-15 2017-03-29 CSL Limited Treatment of neurological conditions
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
KR101806323B1 (ko) 2009-11-13 2017-12-07 다이이치 산쿄 유럽 게엠베하 Ｈｅｒ-３ 관련 질병을 치료하거나 예방하기 위한 물질 및 방법
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
WO2011067711A2 (en) 2009-12-01 2011-06-09 Compugen Ltd Novel heparanase splice variant
EP4382170A3 (en) 2009-12-06 2024-09-04 Bioverativ Therapeutics Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
US9441032B2 (en) 2010-04-07 2016-09-13 Agency For Science, Technology And Research Binding molecules against Chikungunya virus and uses thereof
EP2374816B1 (en) 2010-04-07 2016-09-28 Agency For Science, Technology And Research Binding molecules against Chikungunya virus and uses thereof
WO2011130417A2 (en) 2010-04-15 2011-10-20 Amgen Inc. HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
WO2011145085A2 (en) 2010-05-21 2011-11-24 Procognia (Israel) Ltd Novel antibodies and methods of use for the treatment and diagnosis of cancer
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
AU2011286407A1 (en) 2010-08-06 2013-02-21 Amgen Use of HER3 binding agents in prostate treatment
EP2616100B1 (en) 2010-09-17 2016-08-31 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
EP3838922A1 (en) 2010-10-27 2021-06-23 Amgen Inc. Dkk1 antibodies and methods of use
SG192047A1 (en) 2011-01-24 2013-08-30 Univ Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
JP2014509588A (ja) 2011-03-01 2014-04-21 アムジエン・インコーポレーテツド 二特異性結合剤
JP5908972B2 (ja) 2011-04-07 2016-04-26 アムジエン・インコーポレーテツド 新規な抗原結合タンパク質
WO2012142164A1 (en) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
CA2838833A1 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
EP2724157B1 (en) 2011-06-27 2017-03-08 Valneva Method for screening cells
EP4169525A1 (en) 2011-07-08 2023-04-26 Bioverativ Therapeutics Inc. Factor viii chimeric and hybrid polypeptides, and methods of use thereof
WO2013012855A1 (en) 2011-07-18 2013-01-24 Amgen Inc. Apelin antigen-binding proteins and uses thereof
EA028914B1 (ru) 2011-07-25 2018-01-31 Байоджен Хемофилия Инк. Исследования для мониторинга нарушений свертываемости крови
EP3501536B1 (en) 2011-10-13 2025-12-24 EyePoint Pharmaceuticals, Inc. Treatment of ocular disease
MX363351B (es) 2011-10-13 2019-03-20 Aerpio Therapeutics Inc Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.
MX2014005570A (es) 2011-11-08 2014-05-30 Pfizer El uso de anticuerpos anti factor estimulante de la colonia de macrofagos para tratar trastornos inflamatorios.
AU2012340174A1 (en) 2011-11-16 2014-05-29 Amgen Inc. Methods of treating epidermal growth factor deletion mutant VIII related disorders
WO2013086443A1 (en) 2011-12-08 2013-06-13 Amgen Inc. Agonistic human lcat antigen binding proteins and their use in therapy
EA038705B1 (ru) 2012-01-12 2021-10-07 Биовератив Терапьютикс Инк. Способы снижения иммуногенности фактора свёртывания крови viii у пациентов, получающих лечение фактором viii
HRP20191920T1 (hr) 2012-01-12 2020-01-10 Bioverativ Therapeutics Inc. Kimerni polipeptidi faktora viii i njihova uporaba
WO2013120012A2 (en) 2012-02-08 2013-08-15 Igm Biosciences Inc. Cdim binding proteins and uses thereof
WO2013119419A1 (en) 2012-02-08 2013-08-15 North Carolina State University Treatment of allergic diseases with recombinant antibodies
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
CN104507968B (zh) 2012-04-27 2019-02-05 诺和诺德股份有限公司 人cd30配体抗原结合蛋白
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
JP2015525230A (ja) 2012-06-11 2015-09-03 アムジエン・インコーポレーテツド デュアル受容体アンタゴニスト性抗原結合タンパク質およびその使用
MY177331A (en) 2012-06-15 2020-09-12 Pfizer Improved antagonist antibodies against gdf-8 and uses therefor
US10023628B2 (en) 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
ES2770501T3 (es) 2012-07-11 2020-07-01 Bioverativ Therapeutics Inc Complejo del factor VIII con XTEN y proteína del factor de Von Willebrand y sus usos
WO2014018777A2 (en) 2012-07-25 2014-01-30 Biogen Idec Ma Inc. Blood factor monitoring assay and uses thereof
AU2013331000B2 (en) 2012-10-18 2018-04-19 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
WO2014070953A1 (en) 2012-10-30 2014-05-08 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
ES2664095T3 (es) 2012-12-07 2018-04-18 Pfizer Inc. Fragmentos de anticuerpos monoméricos diseñados mediante ingeniería genética
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
US9383357B2 (en) 2012-12-07 2016-07-05 Northwestern University Biomarker for replicative senescence
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
ES2731681T3 (es) 2013-02-22 2019-11-18 Abbvie Stemcentrx Llc Conjugados de anticuerpo anti-DLL3 y PBD y usos de los mismos
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
WO2014159764A1 (en) 2013-03-14 2014-10-02 Amgen Inc. Chrdl-1 antigen binding proteins and methods of treatment
ES2926798T3 (es) 2013-03-15 2022-10-28 Bioverativ Therapeutics Inc Formulaciones de polipéptido de factor VIII
KR102215405B1 (ko) 2013-03-15 2021-02-10 암젠 인크 인간 pac1 항체
US9850297B2 (en) 2013-03-15 2017-12-26 Amgen Inc. Secreted frizzle-related protein 5 (SFRP5) binding proteins
WO2014165422A1 (en) 2013-04-02 2014-10-09 Merck Sharp & Dohme Corp. Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
US10239951B2 (en) 2013-05-08 2019-03-26 Zymeworks Inc. Bispecific HER2 and HER3 antigen binding constructs
KR20230007555A (ko) 2013-06-28 2023-01-12 바이오버라티브 테라퓨틱스 인크. Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도
JP6267792B2 (ja) 2013-06-28 2018-01-24 アムジエン・インコーポレーテツド ホモ接合性家族性高コレステロール血症の治療方法
US9770461B2 (en) 2013-08-02 2017-09-26 California Institute Of Technology Tailored glycopolymers as anticoagulant heparin mimetics
US10227370B2 (en) 2013-08-02 2019-03-12 California Institute Of Technology Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity
EP3875106A1 (en) 2013-08-08 2021-09-08 Bioverativ Therapeutics Inc. Purification of chimeric fviii molecules
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
JP2016531915A (ja) 2013-08-28 2016-10-13 ステムセントリックス， インコーポレイテッド 部位特異的抗体コンジュゲーション方法および組成物
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение
WO2015173756A2 (en) 2014-05-16 2015-11-19 Pfizer Inc. Bispecific antibodies
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
CA2957722C (en) 2014-08-19 2022-05-31 Merck Sharp & Dohme Corp. Anti-tigit antibodies
CA2956726C (en) 2014-08-27 2023-06-06 Amgen Inc. Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
WO2016040767A2 (en) 2014-09-12 2016-03-17 Amgen Inc. Chrdl-1 epitopes and antibodies
MX378108B (es) 2014-09-16 2025-03-10 Servier Lab Anticuerpos anti-met y composiciones.
TWI728953B (zh) 2015-04-24 2021-06-01 美商安美基公司 治療或預防偏頭痛之方法
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх
WO2020251537A1 (en) * 2019-06-10 2020-12-17 CHO Plus Inc. Cell lines for high level production of protein-based pharmaceuticals
PL3368572T5 (pl) 2015-10-02 2026-07-20 Les Laboratoires Servier Przeciwciała anty-PD-1 oraz kompozycje
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
US20180320136A1 (en) 2015-11-03 2018-11-08 GlycoMimitics, Inc. Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
CA3002883A1 (en) 2015-11-03 2017-05-11 Glycomimetics, Inc. Antibodies for targeting cancer stem cells and treating aggressive cancers
BR112018012352A2 (pt) 2015-12-16 2018-12-11 Merck Sharp & Dohme Corp. anticorpos anti-lag3 e fragmentos de ligação ao antígeno
CN117106085A (zh) 2015-12-23 2023-11-24 美国安进公司 使用gipr结合蛋白与glp-1激动剂的组合来治疗或改善代谢病症的方法
CN116693685A (zh) 2016-04-12 2023-09-05 法国施维雅药厂 抗tim-3抗体及组合物
EP3445393B1 (en) 2016-04-20 2026-01-14 Merck Sharp & Dohme LLC Cmv neutralizing antigen binding proteins
RU2680011C2 (ru) 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
US11390676B2 (en) 2016-10-13 2022-07-19 Symphogen A/S Anti-LAG-3 antibodies and compositions
JP7127859B2 (ja) 2016-11-09 2022-08-30 ノース カロライナ ステート ユニバーシティ キメラタンパク質を用いたアレルギー疾患の治療
TWI780083B (zh) 2016-11-18 2022-10-11 丹麥商賽門弗鎮公司 抗pd-1抗體及組成物
CA3044838A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
WO2018102746A1 (en) 2016-12-02 2018-06-07 Rigel Pharmaceuticals, Inc. Antigen binding molecules to tigit
KR20190090827A (ko) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
EP4480537A3 (en) 2017-01-17 2025-03-12 Amgen Inc. Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
AU2018247916B2 (en) 2017-04-05 2025-04-24 Les Laboratoires Servier Combination therapies targeting PD-1, TIM-3, and LAG-3
JP7160833B2 (ja) 2017-04-13 2022-10-25 サイロパ ビー．ブイ． 抗ｓｉｒｐアルファ抗体
RU2665790C1 (ru) 2017-04-17 2018-09-04 Закрытое Акционерное Общество "Биокад" Моноклональное антитело к pd-l1
JOP20190259A1 (ar) 2017-05-31 2019-10-31 Amgen Inc بروتينات ربط مولد ضد مضادة لـ jagged1
CA3062194A1 (en) 2017-06-20 2018-12-27 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
JP7250706B2 (ja) 2017-06-21 2023-04-03 アムジエン・インコーポレーテツド 胃抑制ペプチド受容体（ｇｉｐｒ）に対するアンタゴニスト結合タンパク質／ｇｌｐ－１受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法
KR102787394B1 (ko) 2017-07-14 2025-03-26 화이자 인크. MAdCAM에 대한 항체
MA68842B1 (fr) 2017-08-04 2025-01-31 Amgen Inc. Procédé de conjugaison de cys-mabs
EA039662B1 (ru) 2017-10-03 2022-02-24 Закрытое Акционерное Общество "Биокад" Антитела, специфичные к cd47 и pd-l1
RU2698048C2 (ru) 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
WO2019108806A1 (en) 2017-11-29 2019-06-06 Board Of Regents Of The University Of Texas System Compositions and methods for cancer therapy
EP3638698B1 (en) 2018-01-26 2021-03-03 Regeneron Pharmaceuticals, Inc. Anti-tmprss2 antibodies and antigen-binding fragments
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
WO2019183437A1 (en) 2018-03-23 2019-09-26 North Carolina State University Methods and compositions for antibody to high affinity receptor for ige
WO2019190931A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Anti-pfrh5 antibodies and antigen-binding fragments thereof
CN116854816A (zh) 2018-04-02 2023-10-10 阿拉玛布治疗学股份有限公司 连接蛋白43抗体及其用途
KR102914074B1 (ko) 2018-05-18 2026-01-16 바이오버라티브 테라퓨틱스 인크. A형 혈우병의 치료 방법
KR102895164B1 (ko) 2018-07-16 2025-12-04 리제너론 파마슈티칼스 인코포레이티드 항-il36r 항체
RU2706298C1 (ru) 2018-09-14 2019-11-15 Закрытое Акционерное Общество "Биокад" НУКЛЕАЗА PaCas9
RU2724469C2 (ru) 2018-10-31 2020-06-23 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с cd20
CN113474370B (zh) 2019-02-01 2025-04-01 瑞泽恩制药公司 抗IL2受体γ抗原结合蛋白
AU2020219112A1 (en) 2019-02-04 2021-08-26 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
EP3941941A1 (en) 2019-03-22 2022-01-26 Regeneron Pharmaceuticals, Inc. Egfr x cd28 multispecific antibodies
RU2734432C1 (ru) 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с GITR
DK3993876T3 (en) 2019-07-01 2024-12-02 Tonix Pharma Ltd Anti-cd154 antibodies and uses thereof
EP4004041A1 (en) 2019-07-26 2022-06-01 Amgen Inc. Anti-il13 antigen binding proteins
EP4025605A1 (en) 2019-09-06 2022-07-13 Symphogen A/S Anti-cd73 antibodies
RU2753282C2 (ru) 2019-09-19 2021-08-12 Закрытое Акционерное Общество "Биокад" ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
WO2021091906A1 (en) 2019-11-04 2021-05-14 Amgen Inc. Methods for treating leukemia
MX2022006751A (es) 2019-12-06 2022-08-19 Regeneron Pharma Minitrampas de vegf y metodos de uso de las mismas.
AU2021219671A1 (en) 2020-02-10 2022-07-14 Regeneron Pharmaceuticals, Inc. Anti-Tmprss2 Antibodies and Antigen-Binding Fragments
CR20220552A (es) 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
JP2023524464A (ja) 2020-04-30 2023-06-12 サイロパ ビー．ブイ． 抗ｃｄ１０３抗体
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
MX2022014598A (es) 2020-05-26 2023-03-31 Regeneron Pharma Anticuerpos anti-glicoproteína espicular sars-cov-2 y fragmentos de unión al antígeno.
IT202000015754A1 (it) 2020-06-30 2021-12-30 Fond Toscana Life Sciences Antibodies to coronavirus
WO2022003530A1 (en) 2020-06-30 2022-01-06 Fondazione Toscana Life Sciences Neutralizing antibodies to sars coronavirus-2
EP4185322A2 (en) 2020-07-24 2023-05-31 Amgen Inc. Immunogens derived from sars-cov2 spike protein
WO2022023292A2 (en) 2020-07-31 2022-02-03 Friedrich-Alexander-Universität Erlangen-Nürnberg Corona virus spike protein-targeting antibodies and use thereof
IT202100003470A1 (it) 2021-02-16 2022-08-16 Fond Toscana Life Sciences Vaccines against sars-cov-2
WO2022187626A1 (en) 2021-03-05 2022-09-09 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments
EP4370210A1 (en) 2021-07-14 2024-05-22 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
WO2023094980A1 (en) 2021-11-23 2023-06-01 Fondazione Toscana Life Sciences Antibodies to coronavirus
WO2023155902A1 (en) 2022-02-18 2023-08-24 Chongqing Mingdao Haoyue Biotechnology Co., Ltd. Intranasal formulations and anti-sars-cov-2-spike protein antibodies
CA3243669A1 (en) 2022-03-11 2023-09-14 Regeneron Pharmaceuticals, Inc. ANTI-GLP1R ANTIBODY-DRUG CONJUGATES INCLUDING GLP1 PEPTIDOMIMETS AND THEIR USES
US20250215091A1 (en) 2022-03-25 2025-07-03 Les Laboratoires Servier Anti-GAL3 Antibodies and Compositions
CN120659627A (zh) 2022-07-29 2025-09-16 瑞泽恩制药公司 用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法
IL318627A (en) 2022-07-29 2025-03-01 Regeneron Pharma Anti-TFR charge fusions and methods of using them
WO2024050526A1 (en) 2022-09-02 2024-03-07 Biomarin Pharmaceutical Inc. Compositions and methods for treating long qt syndrome
CN120456916A (zh) 2022-11-14 2025-08-08 瑞泽恩制药公司 抗fgfr3抗体和抗原结合片段及其使用方法
AU2023379457A1 (en) 2022-11-14 2025-05-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
IT202300000924U1 (it) 2023-01-23 2024-12-22 Philomena Dove Cucitura all-up leggins seamless
AU2024277829A1 (en) 2023-05-19 2025-12-04 Les Laboratoires Servier Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof
JP2026524011A (ja) 2023-07-10 2026-07-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 二重特異性ｐｄ－ｌ１×ｃｄ２８抗体およびそれらの使用方法
JP2026524012A (ja) 2023-07-10 2026-07-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 二重特異性ｐｄ－ｌ１×４－１ｂｂ抗体およびそれらの使用方法
IT202300015579A1 (it) 2023-07-25 2025-01-25 Fond Toscana Life Sciences Anticorpi contro covid-19 e altri coronavirus umani
WO2025046393A1 (en) 2023-08-25 2025-03-06 Fondazione Per L’Istituto Oncologico Di Ricerca (Ior) Reagents against human endogenous retroviruses to target cancer cells
IT202300026115A1 (it) 2023-12-06 2025-06-06 Fond Per L’Istituto Oncologico Di Ricerca Ior Una strategia basata su anticorpi che mira ad erg oncogenico attivato nel cancro alla prostata
IT202400004828A1 (it) 2024-03-05 2025-09-05 Fond Toscana Life Sciences Proteine spike mutate come vaccini contro sars-cov-2
WO2025199030A1 (en) 2024-03-18 2025-09-25 Amgen Inc. Glp-1 receptor agonists and their medical use
DE212025000115U1 (de) 2024-07-30 2026-06-18 Sairopa B.V. Anti-SIRP Alpha-Antikörperformulierungen und ihre Verwendung
WO2026050255A2 (en) 2024-08-27 2026-03-05 Regeneron Pharmaceuticals, Inc. Anti-slc3a2-apis antigen-binding proteins and methods of use thereof
WO2026096576A1 (en) 2024-10-30 2026-05-07 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules that bind psma and 4-1bb and methods of use thereof
US20260146100A1 (en) 2024-10-30 2026-05-28 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules that bind cd22 and 4-1bb and methods of use thereof

Also Published As

Publication number Publication date
US4912040A (en) 1990-03-27
KR890700164A (ko) 1989-03-10
AU1100288A (en) 1988-06-01
CA1297436C (en) 1992-03-17
EP0289597A4 (en) 1990-03-27
JPH01501363A (ja) 1989-05-18
EP0289597A1 (en) 1988-11-09
EP0289597B1 (en) 1994-02-02
WO1988003558A1 (en) 1988-05-19
DE3789017D1 (en) 1994-03-17

Similar Documents

Publication Publication Date Title
BG60107B2 (bg) Метод за получаване на еукариотен полипептид
EP0260148A3 (en) Improved recombinant expression method, vector and transformed cells
AP1678A (en) Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
DE3851399D1 (de) Transientes Expressionssystem zur Herstellung von rekombinantem Protein.
GB2091271B (en) Recombinant dna
EP0088195A3 (en) Messenger rna, production and use thereof
TW200516144A (en) Novel bone mineralization proteins, DNA, vectors, expression systems
IL83192A (en) Method for the preparation of proteins with factor viii activity by microbial host cells;expression vectors,host cells,antibodies
MX428A (es) Region regulatoria para expresion de gen heterologa en levadura.
AU600253B2 (en) Expression of eucaryotic proteins
DK308586A (da) Dna-sekvens, der koder for et specifikt protein, rekombinantvektor, der omfatter sekvensen, og celler, der er transficerede til ekspression af proteinet
DE3851035D1 (de) Interleukin-7.
EP0182448A3 (en) Production of factor viii and related products
EP0111814A3 (en) The cloning and expression of nucleotide sequences encoding bovine growth hormone
ES8706208A1 (es) Un metodo para preparar proteinas que son inmunologicamente reactivas con anticuerpos para virus asociados con linfadenopatia
BG50281A3 (bg) Метод за получаване на рекомбинантн днк експресионен вектор
BG45219A3 (bg) Метод за получаване на вектор на рекомбинантна днк,съдържащ част от изопеницилин синтеза на цефалоспориум акремониум
EP0255320A3 (en) Production of proteins in myeloma cells
EP0196223A3 (en) Dedicated ribosomes and their use in producing protein in cell culture
ES8405842A1 (es) Procedimiento de producir razas estables de celulas de mamiferos
ATE181115T1 (de) Stabilisierung von messenger-rns in tierischen zellen
KR880003008A (ko) 우역 바이러스의 항원 단백질을 코드화 하는 dna
BR8605221A (pt) Metodo de expressao de genes em levedura,fragmento de dna e plasmidio
DE58909205D1 (de) Expressionsvektor und Verfahren zur regulierbaren Herstellung von Proteinen in Eukaryonten.
WO2000037682A8 (en) Method for augmenting expression of a foreign gene

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19901114